<DOC>
	<DOCNO>NCT00823979</DOCNO>
	<brief_summary>This 96 week study determine UK- 453,061 combination Darunavir /ritonavir Nucleos ( ) ide Reverse Transcriptase inhibitor efficacious , safe tolerable etravirine combination Darunavir /ritonavir Nucleos ( ) ide Reverse Transcriptase inhibitor HIV-1 infect patient previously treat antiretroviral drug NNRTI resistance mutation .</brief_summary>
	<brief_title>A Phase 2B Multicenter , Randomized , Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos ( ) Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1</brief_title>
	<detailed_description>The trial terminate 12 April , 2012 due lack efficacy Week 24 analysis . The decision terminate trial base safety concern .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Etravirine</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Male female least 18 year age available followup period least 96 week . HIV 1 RNA viral load great 500 copies/mL . Negative urine pregnancy test . Suspected document active , untreated HIV1 relate opportunistic infection condition require acute therapy time randomization . Subjects acute Hepatitis B and/or C within 30 day randomization . Previous use Darunavir etravirine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>HIV-1 NNRTI Treatment Experienced</keyword>
	<keyword>may Protease inhibitor experience</keyword>
</DOC>